-
-
-
-
-
-
-
Intercept Pharma (ICPT) Misses Q4 EPS by 7c
-
-
-
-
-
-
-
Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update
-
-
-
-
-
-
-
Intercept Pharma (ICPT) Tops Q2 EPS by 88c
-
-
-
-
-
-
-
Intercept Pharma (ICPT) Misses Q4 EPS by 11c, Revenues Miss
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Intercept Pharmaceuticals (ICPT) PT Raised to $56 at BMO Capital, Following Earnings
-
974,855 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All